NIA's two brand new stock suggestions Entheon Biomedical (CSE: ENBI) and Delic Holdings (CSE: DELC) both closed yesterday at new all-time highs!
ENBI gained by 20.19% yesterday to a new all-time high of $1.25 per share on volume of 1.903 million shares (its second highest volume day in history)!
DELC gained by 10.29% yesterday to a new all-time high of $0.75 per share on volume of 583,950 shares (its second highest volume day in history)!
The Drug and Alcohol Testing Association of Canada (DATAC) posted about ENBI last night on their web site! Click here to see for yourself!
According to DATAC, "The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT. DMT is a hallucinogenic compound and is one of the main active ingredients in ayahuasca, a South American preparation used in shamanistic rituals, and can be extracted from several plants. Its effects are also more transient in contrast to those of other psychedelics, such as LSD and hallucinogenic mushrooms. In addition, DMT has already been shown to be safe to use. Entheon Biomedical has made an agreement with the Centre for Human Drug Research (CHDR) located in Leiden, Netherlands, to carry out an early phase clinical trial with DMT on humans."
ENBI is the only publicly traded pure DMT play and there is more buzz about DMT right now than any other psychedelic! Many of the world's most successful entrepreneurs including Tony Robbins and Joe Rogan have all been talking about the benefits of DMT!
DELC is a company that will be generating revenue in the near-term. It has a major imminent catalyst. DELC's co-founder was featured on January 13th in a YouTube interview where he said that because ketamine is currently the only federally legal psychedelic therapy, DELC is going to build out a framework of ketamine clinics that can later offer additional psychedelic therapies as they become legalized. He indicated that DELC would be announcing the acquisition of a revenue generating ketamine-focused psychedelic company in the upcoming weeks, which means it could be any day now: click here to see for yourself!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from ENBI of USD$30,000 cash for a three-month marketing contract. NIA has received compensation from DELC of USD$25,000 cash and expects to receive 150,000 shares of restricted DELC stock for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.